NF-κB as a target for cancer therapy
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
NF-kappaB transcription factors and the signaling pathways that activate them play a critical role in cancer development, progression and therapy, and recently have become a focal point for intense drug discovery and development efforts. This article presents a critical review on the different types of inhibitors targeting the NF-kappaB pathway at several stages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB regulation in the immune system
Li, Q., & Verma, I. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri910 · Cited by 4,007
Missing Pieces in the NF-κB Puzzle
Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638 · cited 3×
“The specific role of IKKα in the activation of the alternative pathway, which is pivotal for the B-cell-mediated responses, the organization of lymphoid organs and the mammary gland development [3], indicate that IKKα may be an attractive approach to treat cancer and autoimmune disease [50].”
BackgroundNuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519 · cited 1×
“Interestingly, in different models NF-κB tumor promotion and progression activity has been demonstrated to depend largely on production of pro-inflammatory cytokines TNF-α or IL-6 and antiagiogenic chemokines IL-8 and Gro1 [40].”
BackgroundNF-κB at the crossroads of life and death
Karin, M., & Lin, A. (2002) · Nature Immunology · doi:10.1038/ni0302-221 · Cited by 2,709 · cited 1×
“The liberated NF-κB dimers translocate to the nucleus, where they coordinate transcriptional activation of several hundred target genes encoding cytokines, growth factors, cell adhesion molecules and proapoptotic and antiapoptotic proteins [3,13].”
BackgroundIKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J., & Vane, J. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11693 · Cited by 1,659
Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B
Wahl, C., Liptay, S., Adler, G., & Schmid, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci992 · Cited by 742
Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer
Rajkumar, S. V., Richardson, P. G., Hideshima, T., & Anderson, K. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.030 · Cited by 569 · cited 1×
“Recently, proteasome inhibitors that have shown promising anticancer responses both in vitro and in vivo have been introduced into human cancer treatment [99].”
BackgroundTakada, Y., Mukhopadhyay, A., Kundu, G. C., Mahabeleshwar, G. H., Singh, S., & Aggarwal, B. B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212389200 · Cited by 495
Schoonbroodt, S., Ferreira, V., Best-Belpomme, M., Boelaert, J. R., Legrand-Poels, S., Korner, M., & Piette, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4292 · Cited by 263
Cited by
Salminen, A., Huuskonen, J., Ojala, J., Kauppinen, A., Kaarniranta, K., & Suuronen, T. (2008) · Ageing Research Reviews · doi:10.1016/j.arr.2007.09.002 · Cited by 581
Pharmaceutically active secondary metabolites of marine actinobacteria
Manivasagan, P., Venkatesan, J., Sivakumar, K., & Kim, S.-K. (2014) · Microbiological Research · doi:10.1016/j.micres.2013.07.014 · Cited by 416
Li, F., & Sethi, G. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.01.002 · Cited by 398
Antitumor compounds from marine actinomycetes
Olano, C., Méndez, C., & Salas, J. A. (2009) · Marine Drugs · doi:10.3390/md7020210 · Cited by 330
“NFκB regulates the expression of a number of genes, the products of which are involved in tumorigenesis [118,119].”
BackgroundThe Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Worzfeld, T., Pogge von Strandmann, E., Huber, M., Adhikary, T., Wagner, U., Reinartz, S., & Müller, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00024 · Cited by 288
Metadata
- Authors
- Melisi, D., & Chiao, P. J.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2007-01-17
- Volume
- 11
- Issue
- 2
- Pages
- 133-144
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2129036315
- Cited by
- 99
- References
- 11
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NF-κB as a target for cancer therapy. https://app.cochat.ai/papers/10.1517/14728222.11.2.133
- The paper
- Melisi, D., & Chiao, P. J. (2007). NF-κB as a target for cancer therapy. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728222.11.2.133
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.